Cyclobenzaprine Hydrochloride
NDC 63304-216
Product Information
Cyclobenzaprine Hydrochloride is a ANDA-approved product labeled by Ranbaxy Pharmaceuticals Inc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a orange product. This product entry covers the primary NDC 63304-216 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
WHITE (C48325)
YELLOW (C48330)
RE80
RE33
RE67
Code Structure Chart
Product Details
What is NDC 63304-216?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYCLOBENZAPRINE HYDROCHLORIDE (UNII: 0VE05JYS2P)
- CYCLOBENZAPRINE (UNII: 69O5WQQ5TI) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)
- STARCH, PREGELATINIZED CORN (UNII: O8232NY3SJ)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 828299 - cyclobenzaprine HCl 7.5 MG Oral Tablet
- RxCUI: 828299 - cyclobenzaprine hydrochloride 7.5 MG Oral Tablet
- RxCUI: 828320 - cyclobenzaprine HCl 5 MG Oral Tablet
- RxCUI: 828320 - cyclobenzaprine hydrochloride 5 MG Oral Tablet
- RxCUI: 828348 - cyclobenzaprine HCl 10 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.